Physician profile
Moe Amadpour
NPI 1508965476
$37,158.52
in general payments reported to CMS, 2019-2025
36 companies · $3,486 in 2025
The $3,486 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $8,977 · 2021: $4,880 · 2022: $3,355 · 2023: $2,718 · 2024: $3,321 · 2025: $3,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,099 · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,099.24 |
| Education | $425.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,192.68 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $4,283.47 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Allergan, INC. | $3,792.58 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,051.15 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $913.32 | 2019-2025 | Vemlidy |
| Celgene Corporation | $713.32 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $642.66 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $582.78 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $543.93 | 2019-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $519.36 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $473.32 | 2019-2022 | |
| Madrigal Pharmaceuticals | $456.80 | 2024-2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $369.59 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $336.82 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $257.13 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $250.76 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Redhill Biopharma INC. | $248.63 | 2020-2023 | Talicia, Aemcolo |
| Ironwood Pharmaceuticals, INC | $246.58 | 2019-2024 | Linzess |
| Pfizer INC. | $192.85 | 2019-2024 | |
| Novo Nordisk INC | $184.08 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $155.06 | 2023-2025 | Dupixent |
| Evoke Pharma, INC. | $110.09 | 2022-2023 | Gimoti |
| Boston Scientific Corporation | $104.80 | 2020 | |
| Intercept Pharmaceuticals, INC. | $98.43 | 2020-2024 | Ocaliva |
| Endogastric Solutions, INC | $90.49 | 2019 | |
| Daiichi Sankyo INC. | $83.60 | 2021 | |
| Merck Sharp & Dohme LLC | $78.70 | 2019 | |
| Capsovision, INC. | $32.72 | 2025 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $31.26 | 2024-2025 | Iqirvo |
| Biocon Biologics INC | $24.01 | 2025 | Yesintek |
| Lucid Diagnostics INC. | $22.69 | 2023 | |
| Nestle Healthcare Nutrition INC. | $19.73 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.06 | 2022 | |
| Braintree Laboratories, INC. | $15.20 | 2023 | Sutab |
| Alfasigma USA, INC. | $12.86 | 2020 | |
| Organon LLC | $11.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moe Amadpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.